slu-pp-332 and retatrutide together SLU-PP-332- Injectable Peptide SLU-PP-332 5mg Peptide - Research

Rosemary Daly, D.O., DABPM Board-Certified Obesity Medicine Physician Janna Goldfeld, PA-C Medical Weight Loss & Primary Care Karla K

Leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

The averages in clinical trials run by the drugs manufacturer were: Wegovy (injection): 15% weight loss in 68 weeks Wegovy (pill): 14% weight loss in 64 weeks Ozempic: 7% weight loss in 30 weeks Rybelsus: 4% weight loss in 6 months These statistics are from clinical trials, where the research team controls many of the variables

Ozempic (semaglutide) is a GLP1 single agonist (~1520% weight loss)

It means researchers are still testing where it may fit, who may benefit, and what risks appear with longer follow-up

Accessed May 24,2012 Liddle RA